口服HIF-PHI抑制剂FG-4592治疗中国CKD贫血的2期研究
两项中国2期研究分别纳入91例非透析和87例透析的CKD贫血患者,评估口服FG-4592的疗效与安全性。非透析研究中低、高剂量组Hb升高≥1 g/dL的比例分别为80.0%和87.1%,显著高于安慰剂组的23.3%(P<0.0001);透析研究中中、高剂量组维持Hb水平优于促红素组。FG-4592耐受性良好,可能成为CKD贫血的有效替代治疗。
要点
- 非透析CKD贫血患者中FG-4592低、高剂量组Hb升高≥1 g/dL比例显著高于安慰剂。
- 透析患者中FG-4592中、高剂量组维持Hb水平优于促红素持续治疗。
- FG-4592治疗组胆固醇显著降低,铁代谢指标稳定或升高,且未静脉补铁。
核心结论
- FG-4592可能成为CKD贫血的有效替代治疗,目前正在全球3期项目中研究。
研究设计与样本
- 非透析研究随机分配91例至低剂量(1.1-1.75 mg/kg)、高剂量(1.50-2.25 mg/kg)FG-4592或安慰剂组。
- 透析研究纳入87例至低剂量(1.1-1.8 mg/kg)、中剂量(1.5-2.3 mg/kg)、高剂量(1.7-2.3 mg/kg)FG-4592或促红素持续治疗组。
- 两项研究均仅允许口服铁剂补充。
主要发现
- 非透析研究中低剂量组80.0%、高剂量组87.1%的患者Hb较基线升高≥1 g/dL,安慰剂组为23.3%(P<0.0001)。
- 透析研究中低、中、高剂量组分别有59.1%、88.9%(P=0.008)、100%(P=0.0003)的患者在5-6周后维持Hb水平,促红素组为50%。
- FG-4592治疗组胆固醇显著降低,血清铁、总铁结合力(TIBC)和转铁蛋白稳定或升高。
- 非透析研究中所有FG-4592组hepcidin水平显著降低,安慰剂组无变化;透析研究中最高剂量组hepcidin呈显著剂量依赖性降低。
- FG-4592组与对照组不良事件相似。
临床怎么用
- 口服FG-4592可有效提升或维持CKD贫血患者Hb水平,且无需静脉补铁。
- FG-4592治疗可能伴随胆固醇降低和hepcidin下降,需关注其代谢效应。
局限性
- 两项均为2期研究,样本量有限,尚需3期研究确认长期疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: FG-4592 (roxadustat) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) promoting coordinated erythropoiesis through the transcription factor HIF. Two Phase 2 studies were conducted in China to explore the safety and efficacy of FG-4592 (USAN name: roxadustat, CDAN name: ), a HIF-PHI, in patients with anemia of chronic kidney disease (CKD), both patients who were dialysis-dependent (DD) and patients who were not dialysis-dependent (NDD). METHODS: In the NDD study, 91 participants were randomized to low (1.1-1.75 mg/kg) or high (1.50-2.25 mg/kg) FG-4592 starting doses or to placebo. In the DD study, 87 were enrolled to low (1.1-1.8 mg/kg), medium (1.5-2.3 mg/kg) and high (1.7-2.3 mg/kg) starting FG-4592 doses or to continuation of epoetin alfa. In both studies, only oral iron supplementation was allowed. RESULTS: In the NDD study, hemoglobin (Hb) increase ≥1 g/dL from baseline was achieved in 80.0% of subjects in the low-dose cohort and 87.1% in the high-dose cohort, versus 23.3% in the placebo arm (P < 0.0001, both). In the DD study, 59.1%, 88.9% (P = 0.008) and 100% (P = 0.0003) of the low-, medium- and high-dose subjects maintained their Hb levels after 5- and 6-weeks versus 50% of the epoetin alfa-treated subjects. In both studies, significant reductions in cholesterol were noted in FG-4592-treated subjects, with stability or increases in serum iron, total iron-binding capacity (TIBC) and transferrin (without intravenous iron administration). In the NDD study, hepcidin levels were significantly reduced across all FG-4592-treated arms as compared with no change in the placebo arm. In the DD study, hepcidin levels were also reduced in a statistically significant dose-dependent manner in the highest dose group as compared with the epoetin alfa-treated group. Adverse events were similar for FG-4592-treated and control subjects. CONCLUSIONS: FG-4592 may prove an effective alternative for managing anemia of CKD. It is currently being investigated in a pivotal global Phase 3 program.
引用
- Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017. PMID: 28371815. doi:10.1093/ndt/gfx011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。